Literature DB >> 26699701

Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies.

Frederike M J Reischies1, Reinhard B Raggam2, Juergen Prattes1, Robert Krause1, Susanne Eigl3, Agnes List4, Franz Quehenberger5, Volker Strenger6, Albert Wölfler4, Martin Hoenigl7.   

Abstract

Galactomannan (GM) testing of urine specimens may provide important advantages, compared to serum testing, such as easy noninvasive sample collection. We evaluated a total of 632 serial urine samples from 71 patients with underlying hematological malignancies and found that the urine GM/creatinine ratio, i.e., (urine GM level × 100)/urine creatinine level, which takes urine dilution into account, reliably detected invasive aspergillosis and may be a promising diagnostic tool for patients with hematological malignancies. (This study has been registered at ClinicalTrials.gov under registration no. NCT01576653.).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26699701      PMCID: PMC4767980          DOI: 10.1128/JCM.02969-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits.

Authors:  B Dupont; M Huber; S J Kim; J E Bennett
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

2.  Serum and urine galactomannan testing for screening in patients with hematological malignancies.

Authors:  Wiebke Duettmann; Christoph Koidl; Katharina Troppan; Katharina Seeber; Walter Buzina; Albert Wölfler; Jasmin Wagner; Robert Krause; Martin Hoenigl
Journal:  Med Mycol       Date:  2014-06-17       Impact factor: 4.076

3.  Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.

Authors:  M Hoenigl; J Prattes; B Spiess; J Wagner; F Prueller; R B Raggam; V Posch; W Duettmann; K Hoenigl; A Wölfler; C Koidl; W Buzina; M Reinwald; C R Thornton; R Krause; D Buchheidt
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

4.  Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies.

Authors:  Martin Hoenigl; Helmut J F Salzer; Reinhard B Raggam; Thomas Valentin; Angelika Rohn; Albert Woelfler; Katharina Seeber; Werner Linkesch; Robert Krause
Journal:  Med Mycol       Date:  2011-09-12       Impact factor: 4.076

5.  Detection of (1→3)-β-D-glucan in same-day urine and serum samples obtained from patients with haematological malignancies.

Authors:  Reinhard B Raggam; Lara M L Fischbach; Juergen Prattes; Wiebke Duettmann; Susanne Eigl; Frederike Reischies; Albert Wölfler; Jasmin Rabensteiner; Florian Prueller; Robert Krause; Martin Hoenigl
Journal:  Mycoses       Date:  2015-05-11       Impact factor: 4.377

6.  Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis.

Authors:  Rafael F Duarte; Isabel Sánchez-Ortega; Isabel Cuesta; Montserrat Arnan; Beatriz Patiño; Alberto Fernández de Sevilla; Carlota Gudiol; Josefina Ayats; Manuel Cuenca-Estrella
Journal:  Clin Infect Dis       Date:  2014-08-27       Impact factor: 9.079

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.

Authors:  Martin Hoenigl; Volker Strenger; Walter Buzina; Thomas Valentin; Christoph Koidl; Albert Wölfler; Katharina Seeber; Angelika Valentin; Anna T Strohmeier; Ines Zollner-Schwetz; Reinhard B Raggam; Christian Urban; Cornelia Lass-Flörl; Werner Linkesch; Robert Krause
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

9.  Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis.

Authors:  Simon F Dufresne; Kausik Datta; Xinming Li; Ekaterina Dadachova; Janet F Staab; Thomas F Patterson; Marta Feldmesser; Kieren A Marr
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

10.  Galactomannan testing during mold-active prophylaxis.

Authors:  Oliver A Cornely
Journal:  Clin Infect Dis       Date:  2014-08-27       Impact factor: 9.079

View more
  7 in total

1.  Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis.

Authors:  Martin Hoenigl; Thomas Orasch; Klaus Faserl; Juergen Prattes; Juergen Loeffler; Jan Springer; Fabio Gsaller; Frederike Reischies; Wiebke Duettmann; Reinhard B Raggam; Herbert Lindner; Hubertus Haas
Journal:  J Infect       Date:  2018-09-26       Impact factor: 6.072

Review 2.  Lateral Flow Assays for the Diagnosis of Invasive Aspergillosis: Current Status.

Authors:  Sven Heldt; Martin Hoenigl
Journal:  Curr Fungal Infect Rep       Date:  2017-04-29

Review 3.  Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.

Authors:  Toine Mercier; Ellen Guldentops; Katrien Lagrou; Johan Maertens
Journal:  Front Microbiol       Date:  2018-04-04       Impact factor: 5.640

Review 4.  Treatment of Aspergillosis.

Authors:  Jeffrey D Jenks; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2018-08-19

5.  zzm321990 Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology.

Authors:  Genna Davies; Oski Singh; Juergen Prattes; Martin Hoenigl; Paul W Sheppard; Christopher R Thornton
Journal:  J Fungi (Basel)       Date:  2020-12-31

Review 6.  Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.

Authors:  Thomas Lehrnbecher; Angela Hassler; Andreas H Groll; Konrad Bochennek
Journal:  Front Microbiol       Date:  2018-03-26       Impact factor: 5.640

7.  Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement.

Authors:  Jeffrey D Jenks; Jean-Pierre Gangneux; Ilan S Schwartz; Ana Alastruey-Izquierdo; Katrien Lagrou; George R Thompson Iii; Cornelia Lass-Flörl; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2020-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.